HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Visx Inc.

Division of Abbott Medical Optics Inc./Visx Inc.
www.visx.com

Latest From Visx Inc.

Difficult Days for Laser Vision Correction Market and AMO

As economic conditions worsened over the course of 2008, consumers pulled back on discretionary, big-ticket purchases, directly impacting laser vision correction volume trends in the US, including the popular LASIK procedure. At the same time, the cataract surgery market seems to be recession-proof.
Medical Device

Business & Technology Briefs (06/2007)

Brief summaries of recent product and company developments in the device industry, including Aspect Medical's brain monitoring technology, Warburg's bid for Bausch & Lomb, and Frazier Healthcare Venture's investment in publicly-traded Endocare.

The Farsightedness of Refractec

Presbyopia is causing a rapprochement between two distinct types of ophthalmic surgeons--the cataract surgeon implanting intraocular lenses in the elderly, and the refractive surgeon offering private-pay laser vision correction procedures to young adults. Bridging the gap is Refractec, the first company to ever get FDA approval for an ophthalmic surgery technology specifically for presbyopia. Refractec offers a non-cutting treatment that surgeons regard as a "starter treatment" that gets new kinds of patients into refractive surgery practices.
Medical Device

AMO & VISX: Number one in Refractive Surgery

Advanced Medical Optics, a specialist in ophthalmic surgery, has acquired Visx , the largest manufacture of lasers for vision correction surgery, for a combination of cash and stock worth $1.27 billion. Analysts were surprised by the magnitude of the deal, following so soon on the heels of AMO's $450 million purchase of the ophthalmic surgical business of Pfizer in April, which brought it products for the cataract and glaucoma markets. However, this is not simply the merger of two major ophthalmic companies for the purpose of achieving critical mass; the two companies operate in distinct, largely non-overlapping markets, and to all appearances fit together like hand in glove.
Medical Device
See All

Company Information

  • Industry
  • Medical Devices
    • Laser
  • Therapeutic Areas
  • Ophthalmic
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Abbott Medical Optics Inc.
  • Johnson & Johnson
  • Senior Management
  • Elizabeth Davila, Chmn., Pres. & CEO
    Doug H Post, EVP, Operations
    Carol F Harner, VP, R&D
    David M Patino, VP, Regulatory & Clinical Affairs
    Mark B Logan, Chmn.
  • Contact Info
  • Visx Inc.
    Phone: (408) 733-2020
    3400 Central Expressway
    Santa Clara, CA 95051
    USA
UsernamePublicRestriction

Register